ArticleMethods in molecular biology (Clifton, N.J.)2009
Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery.
Article in Methods in molecular biology (Clifton, N.J.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Surveillance for Asiatic filoviruses and zoonotic paramyxoviruses at a perceived wildlife-human interface.Emerging microbes & infections · 2026Article
- Serologic evidence of orthomarburgviruses and an orthoebolavirus in frugivorous Malagasy bats.One health outlook · 2025Article
- Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.Nature communications · 2024Article
- Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.Structure (London, England : 1993) · 2024Article
- Structure and design of Langya virus glycoprotein antigens.bioRxiv : the preprint server for biology · 2023Article
- A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses.Viruses · 2023Article
- Recombinant Soluble Henipavirus Glycoprotein Preparation.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Therapeutic Antibodies: An Overview.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Functional Analysis of the Fusion and Attachment Glycoproteins of Mojiang Henipavirus.Viruses · 2021Article
- Establishment of a longitudinal pre-clinical model of lyssavirus infection.Journal of virological methods · 2020Article
- Serological Evidence for Henipa-like and Filo-like Viruses in Trinidad Bats.The Journal of infectious diseases · 2020Article
- A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein.bioRxiv : the preprint server for biology · 2020Article
- Structural and functional analyses reveal promiscuous and species specific use of ephrin receptors by Cedar virus.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Filovirus-reactive antibodies in humans and bats in Northeast India imply zoonotic spillover.PLoS neglected tropical diseases · 2019Article
- An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections.Nature structural & molecular biology · 2019Article
- Rescue and characterization of recombinant cedar virus, a non-pathogenic Henipavirus species.Virology journal · 2018Article
- Serologic Evidence of Fruit Bat Exposure to Filoviruses, Singapore, 2011-2016.Emerging infectious diseases · 2018Article
- Crystal Structure of the Pre-fusion Nipah Virus Fusion Glycoprotein Reveals a Novel Hexamer-of-Trimers Assembly.PLoS pathogens · 2015Article
- Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins.Journal of virology · 2012Article
- A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.Science translational medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neutralizing antibodies are a critical component in the protection or recovery from viral infections. In the absence of available vaccines or antiviral drugs for many important human viral pathogens, the identification and characterization of new human monoclonal antibodies (hmAbs) that are able to neutralize viruses offers the possibility for effective pre- and/or post-exposure therapeutic modalities. Such hmAbs may also help in our understanding of the virus entry process, the mechanisms of virus neutralization, and in the eventual development of specific entry inhibitors, vaccines, and research tools. The majority of the more recently developed antiviral hmAbs have come from the use of antibody phage-display technologies using both naïve and immune libraries. Many of these agents are also enveloped viruses possessing important neutralizing determinants within their membrane-anchored envelope glycoproteins, and the use of recombinant, soluble versions of these viral glycoproteins is often critical in the isolation and development of antiviral hmAbs. This chapter will detail several methods that have been successfully employed to produce, purify, and characterize soluble and secreted versions of several viral envelope glycoproteins which have been successfully used as antigens to capture and isolate human phage-displayed monoclonal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.